Redeye comments on Medivir's Q2 report. The main event in the quarter was the presentation of an est...
Redeye comments on Active Biotech's Q2 report. New results with naptumomab + docetaxel were presente...
Redeye provides an update following SenzaGen’s Q2 2024 report.
Redeye has made only minor revisions to its forecast following Modelon’s Q2 report, in which the rep...
Arctic Blue Beverages AB (”Arctic Blue Beverages” eller ”Bolaget”) redovisar en minskad nettoomsättn...
2024e-'26e EBIT raised by 5% We are above the upper end of guidance Strong order book and robust out...
Nettoomsättningen för det andra kvartalet uppgick till 10,2 MEURO (9,5), vilket motsvarade en ökning...
ExpreS2ion Biotech har tagit ett steg närmare att inleda en first-in-human studie med sitt bröstcanc...
Redeye comments on Enviro’s Q2 report, which held no surprises.
Interimsdata ger ytterligare stöd Interimsdata som presenterades sent under kvartalet från bolagets ...
Industribolaget AGES Industri presenterade en rapport för det andra kvartalet som var något svagare ...
Idag publicerade Fable Media sin delårsrapport för kv2 2024.
Revenues and EBIT 2 and 14% ahead of expectations Order intake of DKK 2.
Q2 revenue 29% below, won't meet '24 guidance Design win with SigmaX.
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 21 augusti år 202...
Redeye provides its initial take on Navigo’s Q2 2024 report, which came in just slightly below our e...
Redeye’s first comments on the Q2 report this morning.
Redeye raises its base case following the positive readout in the phase IIa RVO study with ANXV.
Solteq had released preliminary Q2 figures ahead of the earnings report and the comparable net sales...
STENOCARE published on August 21st the company’s Q2-report for 2024.
